You are currently viewing the summary.
See the full text- Join / Subscribe
- Buy article
- member account Enable
- Renew subscription
- Recommend a subscription to your library
- Help for librarians
Summary
a drug tetrathiomolybdate (TM), which mops copper in the body, which had already failed in a series of clinical trials on the previous cancer, is to get a second chance. A Phase II clinical trial of the drug in women who had been successfully treated for breast cancer but are at high risk of recurrence suggests that it can inhibit the growth of new tumors. Yet the promise of this copper depletion strategy appears not tarnished by clinical results, but the company strategy. The oncologist who led the Phase II clinical trial will now proceed to a, III TM largest phase of trial. But by TM Cancer Treatment rights are held by a Swedish biotechnology company developing the drug in place of Wilson's disease, a rare inherited disorder of copper accumulation. The company, Wilson Therapeutics, has no immediate plans to test TM in cancer patients, its CEO acknowledged, and for now will not sublicense the drug.
-
↵ * Ken Garber is a writer based in Ann Arbor, Michigan.
0 Komentar